Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus

Theoretical Studies on the Susceptibility of Oseltamivir Against Variants of 2009 A/H1N1 Influenza Neuraminidase.

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Binding Mechanism of Oseltamivir and Influenza Neuraminidase Suggests Perspectives for the Design of New Anti-Influenza Drugs

Insights into Susceptibility of Antiviral Drugs Against the E119G Mutant of 2009 Influenza A (H1N1) Neuraminidase by Molecular Dynamics Simulations and Free Energy Calculations.

Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase

Functional And Structural Analysis Of Influenza Virus Neuraminidase N3 Offers Further Insight Into The Mechanisms Of Oseltamivir Resistance

Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.

Microsecond dynamics of H10N7 influenza neuraminidase reveals the plasticity of loop regions and drug resistance due to the R292K mutation

Discovery of Novel "Dual-Site" Binding Oseltamivir Derivatives As Potent Influenza Virus Neuraminidase Inhibitors.

Structure-Based Optimization of N-Substituted Oseltamivir Derivatives As Potent Anti-Influenza A Virus Agents with Significantly Improved Potency Against Oseltamivir-Resistant N1-H274Y Variant

Residue-based Design of Small Molecule Inhibitor for H1N1, H5N1 and H7N1 Mutants

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

Mutation-induced Spatial Differences in Neuraminidase Structure and Sensitivity to Neuraminidase Inhibitors

Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and Its Implication for Drug Design

Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant

The hydrophobic side chain of oseltamivir influences type A subtype selectivity of Neuraminidase inhibitors.